RESERVED AREA     |
MINDDS
  • Home
  • News
  • MINDDS
  • Activities
    • Meetings
    • Training Schools
    • STSM
    • Conference Grants
    • Publications
  • WG
    • WG1: Patient Cohort Framework
    • WG2: Clinical Phenotyping
    • WG3: Emerging Technologies
    • WG4: Databases and informatics
    • WG5: Integration and Convergence
  • Members
    • Core Group
    • Management Committee
    • Working Groups
    • Participants
    • International Partner countries
    • Geographical Distribution
  • Partners
    • Universities
    • Hospital & Clinical Hospitals
    • Research Institutes
    • Industries
    • Public Health Institutions
    • National Organizations
  • Knowledge Nexus
    • Survey
    • Researchers
    • Clinicians
    • Patients & Families
MINDDS
  • Home
  • News
  • MINDDS
  • Activities
    • Meetings
    • Training Schools
    • STSM
    • Conference Grants
    • Publications
  • WG
    • WG1: Patient Cohort Framework
    • WG2: Clinical Phenotyping
    • WG3: Emerging Technologies
    • WG4: Databases and informatics
    • WG5: Integration and Convergence
  • Members
    • Core Group
    • Management Committee
    • Working Groups
    • Participants
    • International Partner countries
    • Geographical Distribution
  • Partners
    • Universities
    • Hospital & Clinical Hospitals
    • Research Institutes
    • Industries
    • Public Health Institutions
    • National Organizations
  • Knowledge Nexus
    • Survey
    • Researchers
    • Clinicians
    • Patients & Families

Members

MINDDSMembers

Members

  • Core Group
  • Management Committee
  • Working Groups
  • Participants
  • International Partner countries
  • Geographical Distribution

Latest Updates

  • MINDDS WORKSHOP Neurodevelopmental Disorders and Copy Number Variants 18th February 2020
  • Happy 2020 24th December 2019

Download MoU 860 KB

MINDDS

Understanding rare neurodevelopmental disorders (NDD) has the potential drive major new therapies for the common NDD of schizophrenia and Autism Spectrum Disorder (ASD).

Know More

Quick links

  • News
  • MINDDS
  • Activities
  • WG
  • Members
  • Partners

Connect with us

Have a question? Please send us an email to mindds@cardiff.ac.uk
Sign up for MINDDS articles and resources here.

Cost Action

2019 © MINDDS | Privacy Policy | Design by Boutik
Go to Top

MINDDS

Understanding rare neurodevelopmental disorders (NDD) has the potential drive major new therapies for the common NDD of schizophrenia and Autism Spectrum Disorder (ASD).

Download MoU 860 KB